Refine Search

Search Results -

Term	Documents
CD44R2	5
CD44R2S	0
CD44R1	17
CD44R1S	0
(CD44R2 OR CD44R1).PGPB,USPT,EPAB,JPAB,DWPI.	17
((CD44R2 OR CD44R1)).PGPB,USPT,EPAB,JPAB,DWPI.	17

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L4

Refine Search

Recall Text Clear Interrupt

Search History

DATE: Saturday, September 22, 2007 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L4	(CD44R2 or CD44R1)	17	L4
L3	(express$)same(recombinant)same (hemopoie$ or hematopoie$)same (cell$)same(cd44)	4	L3
L2	L1 same (hemopoie$ or hematopoie$ or stem)	30	L2
L1	(cd44H or CD44R2 or CD44R1)	64	L1

END OF SEARCH HISTORY

```
EM:OS  - DIALOG OneSearch
  File   5:Biosis Previews(R) 1926-2007/Sep W2
         (c) 2007 The Thomson Corporation
  File  73:EMBASE 1974-2007/Sep 14
         (c) 2007 Elsevier B.V.
  File 155:MEDLINE(R) 1950-2007/Sep 14
         (c) format only 2007 Dialog
  File 399:CA SEARCH(R) 1967-2007/UD=14712
         (c) 2007 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

      Set  Items  Description
      ---  -----  -----------
? e au=sackstein robert ?

Ref   Items  Index-term
E1        2  AU=SACKSTEIN R.D.
E2      127  AU=SACKSTEIN ROBERT
E3        0 *AU=SACKSTEIN ROBERT ?
E4        1  AU=SACKSTEIN ROBERT D
E5        2  AU=SACKSTEIN ROBERTO
E6        6  AU=SACKSTEIN, R.
E7       41  AU=SACKSTEIN, ROBERT
E8        1  AU=SACKSTEIN, ROBERTO
E9        2  AU=SACKSTEM R
E10     110  AU=SACKSTON W E
E11       1  AU=SACKSTON WALLY E
E12       9  AU=SACKSTON, W. E.

          Enter P or PAGE for more
? s e1-e7
              2  AU=SACKSTEIN R.D.
            127  AU=SACKSTEIN ROBERT
              0  AU=SACKSTEIN ROBERT ?
              1  AU=SACKSTEIN ROBERT D
              2  AU=SACKSTEIN ROBERTO
              6  AU=SACKSTEIN, R.
             41  AU=SACKSTEIN, ROBERT
      S1     179  E1-E7
? s s1 and cd44 or hcam or pgp(w)1 or heremes or hcell)
>>>Unmatched parentheses
? s s1 and (cd44 or hcam or pgp(w)1 or heremes or hcell)
Processing
            179  S1
          22231  CD44
            137  HCAM
          10314  PGP
       12431632  1
            795  PGP(W)1
              1  HEREMES
             36  HCELL
      S2     43  S1 AND (CD44 OR HCAM OR PGP(W)1 OR HEREMES OR HCELL)
? s s1 and (cd44 or hcam or pgp(w)1 or hermes or hcell)
Processing
            179  S1
          22231  CD44
            137  HCAM
          10314  PGP
       12431632  1
            795  PGP(W)1
           5997  HERMES
             36  HCELL
      S3     43  S1 AND (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL)
```

```
? rd s3
      S4       26  RD S3  (unique items)
? s s4 and agonist?(20n)(antibod? or immunoglobulin?)
              26  S4
          562028  AGONIST?
         2252588  ANTIBOD?
          838135  IMMUNOGLOBULIN?
            8475  AGONIST?(20N)(ANTIBOD? OR IMMUNOGLOBULIN?)
      S5        0  S4 AND AGONIST?(20N)(ANTIBOD? OR IMMUNOGLOBULIN?)
? s (cd44 or hcam or pgp(w)1 or hermes or hcell) and (agonist? or
stimulat?)(10n)(antibod? or immunoglobulin?)
Processing
           22231  CD44
             137  HCAM
           10314  PGP
        12431632  1
             795  PGP(W)1
            5997  HERMES
              36  HCELL
          562028  AGONIST?
         2645715  STIMULAT?
         2252588  ANTIBOD?
          838135  IMMUNOGLOBULIN?
           62341  (AGONIST? OR STIMULAT?)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?)
      S6      305  (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL) AND
                   (AGONIST? OR STIMULAT?)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?)
? s (cd44 or hcam or pgp(w)1 or hermes or hcell) and (agonist? or
stimulat?)(10n)(antibod? or immunoglobulin?(10n)(glycan? or saccharide? or
carbohydrate? or cho))
Processing
           22231  CD44
             137  HCAM
           10314  PGP
        12431632  1
             795  PGP(W)1
            5997  HERMES
              36  HCELL
          562028  AGONIST?
         2645715  STIMULAT?
         2252588  ANTIBOD?
          838135  IMMUNOGLOBULIN?
           68296  GLYCAN?
          193199  SACCHARIDE?
          631981  CARBOHYDRATE?
           99572  CHO
            5276  IMMUNOGLOBULIN?(10N)(((GLYCAN? OR SACCHARIDE?) OR
                   CARBOHYDRATE?) OR CHO)
           52884  (AGONIST? OR STIMULAT?)(10N)(ANTIBOD? OR
                   IMMUNOGLOBULIN?(10N)(((GLYCAN? OR SACCHARIDE?) OR
                   CARBOHYDRATE?) OR CHO))
      S7      291  (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL) AND
                   (AGONIST? OR STIMULAT?)(10N)(ANTIBOD? OR
                   IMMUNOGLOBULIN?(10N)(GLYCAN? OR SACCHARIDE? OR
                   CARBOHYDRATE? OR CHO))
? rd s7
      S8      160  RD S7  (unique items)
? s s8 and py=2002
             160  S8
         2431619  PY=2002
      S9       8  S8 AND PY=2002
? rd s9
     S10       8  RD S9  (unique items)
? t s10/3/all
```

10/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16998285 BIOSIS NO.: 200200591796
Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: Role of CD44 receptor in MMC proliferation and haptotaxis
AUTHOR: Nasreen Najmunnisa; Mohammed Kamal A; Hardwick Joyce; Van Horn Robert D; Sanders Kerry; Kathuria Hasmeena; Loghmani Farzad; Antony Veena B (Reprint)
AUTHOR ADDRESS: Veterans' Affairs Medical Center, 1481 West 10th Street, 111-P, Indianapolis, IN, 46202, USA**USA
JOURNAL: Oncology Research 13 (2): p71-78 2002 2002
MEDIUM: print
ISSN: 0965-0407
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

10/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16964237 BIOSIS NO.: 200200557748
CD44 stimulation by fragmented hyaluronic acid induces upregulation and tyrosine phosphorylation of c-Met receptor protein in human chondrosarcoma cells
AUTHOR: Suzuki Mika; Kobayashi Hiroshi (Reprint); Kanayama Naohiro; Nishida Takashi; Takigawa Masaharu; Terao Toshihiko
AUTHOR ADDRESS: Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Handayama 1-20-1. Handacho 3600, Hamamatsu, Shizuoka, 431-3192, Japan**Japan
JOURNAL: Biochimica et Biophysica Acta 1591 (1-3): p37-44 19 August, 2002 2002
MEDIUM: print
ISSN: 0006-3002
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

10/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16833117 BIOSIS NO.: 200200426628
High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6
AUTHOR: Xu B; Broome U; Ericzon B-G; Sumitran-Holgersson S (Reprint)
AUTHOR ADDRESS: Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital AB, F-79, S-141 86, Stockholm, Sweden** Sweden
JOURNAL: Gut 51 (1): p120-127 July, 2002 2002
MEDIUM: print
ISSN: 0017-5749
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

10/3/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16748101 BIOSIS NO.: 200200341612
CD44 variant-specific antibodies trigger hemopoiesis by selective release of cytokines from bone marrow macrophages
AUTHOR: Khaldoyanidi Sophia; Karakhanova Svetlana; Sleeman Jonathan; Herrlich Peter; Ponta Helmut (Reprint)
AUTHOR ADDRESS: Institute of Toxicology and Genetics, Forschungszentrum Karlsruhe, D-76021, Karlsruhe, Germany**Germany
JOURNAL: Blood 99 (11): p3955-3961 June 1, 2002 2002
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

10/3/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2007 Elsevier B.V. All rts. reserv.

11804817 EMBASE No: 2002377264
TNF-alpha increases the carbohydrate sulfation of CD44: Induction of 6-sulfo N-acetyl lactosamine on N- and O-linked glycans
Delcommenne M.; Kannagi R.; Johnson P.
P. Johnson, Section Bone Marrow Transplantation, Rush Presbyterian-St. Lukes Med. Ctr, Chicago, IL 60612 United States
AUTHOR EMAIL: pauline@interchange.ubc.ca
Glycobiology (GLYCOBIOLOGY) (United Kingdom) 01 OCT 2002, 12/10 (613-622)
CODEN: GLYCE ISSN: 0959-6658
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 69

10/3/6 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

14122581 PMID: 12745438
Src-/- fibroblasts are defective in their ability to disassemble focal adhesions in response to phorbol ester/hyaluronan treatment.
Hall Christine L; Wang Fu-Sheng; Turley Eva
Depts. Oncology and Biochemistry, The University of Western Ontario and London Regional Cancer Center, London, Ontario, Canada N6A 4L6.
Cell communication & adhesion (England) Sep-Dec 2002, 9 (5-6) p273-83, ISSN 1541-9061--Print Journal Code: 101096596
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

10/3/7 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

13642410 PMID: 11854356
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance.
Nguyen Linh T; Elford Alisha R; Murakami Kiichi; Garza Kristine M;

Schoenberger Stephen P; Odermatt Bernhard; Speiser Daniel E; Ohashi Pamela S
Departments of Immunology and Medical Biophysics, Ontario Cancer Institute, 610 University Ave., Toronto, Ontario M5G 2M9, Canada.
Journal of experimental medicine (United States) Feb 18 2002, 195 (4) p423-35, ISSN 0022-1007--Print Journal Code: 2985109R
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

10/3/8 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

13626927 PMID: 11829752
Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues.
Politz Oliver; Gratchev Alexei; McCourt Peter A G; Schledzewski Kai; Guillot Pierre; Johansson Sophie; Svineng Gunbjorg; Franke Peter; Kannicht Christoph; Kzhyshkowska Julia; Longati Paola; Velten Florian W; Johansson Staffan; Goerdt Sergij
Department of Dermatology, University Medical Center Mannheim, Ruprecht Karls University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68135 Mannheim, Germany.
Biochemical journal (England) Feb 15 2002, 362 (Pt 1) p155-64, ISSN 0264-6021--Print Journal Code: 2984726R
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
? t s10/kwic/all
>>>KWIC option is not available in file(s): 399

10/KWIC/1 (Item 1 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: Role of CD44 receptor in MMC proliferation and haptotaxis
2002

...ABSTRACT: conjugated hyaluronan. Our results indicate that the MMC line that expressed the highest amount of CD44 receptor showed increased proliferation and haptotactic migration of MMC when stimulated with LMWHA but not HMWHA. Monoclonal ***antibody*** against ***CD44*** inhibited proliferation by about 12-40% and migration by 10-35% in the MMC lines...

...binding to MM cell surface was significantly higher than HMWHA. This directly correlated with their ***CD44*** receptor expression. Neutralization of CD44 receptor significantly reduced the LMMHA binding to MMC. These results provide evidence that the interaction between the adhesive protein receptor CD44 and extracellular matrix component (HA) transmits regulatory signals for mediating the locomotion and proliferation of...
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: ***CD44*** receptor...

...anti- ***CD44*** monoclonal antibody...

10/KWIC/2 (Item 2 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

CD44 stimulation by fragmented hyaluronic acid induces upregulation and tyrosine phosphorylation of c-Met receptor protein...
2002

...ABSTRACT: Since HGF/SF receptor, c-Met, is expressed by tumor cells, and since stimulation of CD44, a transmembrane glycoprotein known to bind hyaluronic acid (HA) in its extracellular domain, is involved in activation of c-Met, we have studied the effects of CD44 stimulation by ligation with HA upon the expression and tyrosine phosphorylation of c-Met on humanchondrosarcoma cell line HCS-2/8. The current study indicates that (a) CD44 stimulation by fragmented HA upregulates expression of c-Met proteins; (b) fragmented HA also induces ...

...are active with maximal effect in the mug/ml range; (d) the standard form of CD44 (CD44s) is critical for the response because the effect on c-Met, both in terms of upregulation and phosphorylation, is inhibited by preincubation with an anti-CD44 monoclonal antibody; and (c) phosphorylation of c-Met induced by CD44 stimulation is inhibited by protein tyrosine kinase inhibitor, tyrphostin. Therefore, our study represents the first report that CD44 stimulation induced by fragmented HA enhances c-Met expression and tyrosine phosphorylation in human chondrosarcoma cells. Taken together, these studies establish a signal transduction cascade or cross-talk emanating from ***CD44*** to c-Met.
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: ***CD44*** ; ...

... ***CD44*** stimulation

10/KWIC/3 (Item 3 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

...in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6
2002

...ABSTRACT: hepatitis (AIH; n=25), and normal controls (n=12) were investigated for the presence of antibodies that reacted with unstimulated and cytokine stimulated BECs isolated from a normal healthy liver. To demonstrate organ specificity, lung epithelial cells (LECs...

...but not PBC and AIH sera induced significantly increased expression of the cell adhesion molecule ***CD44*** . Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and western blot analysis of BEC membranes demonstrated a...
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: CD44;

10/KWIC/4 (Item 4 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

CD44 variant-specific antibodies trigger hemopoiesis by selective release of cytokines from bone marrow macrophages
2002

...ABSTRACT: role in this process. Using long-term bone marrow cultures, we show here that monoclonal antibodies directed against the CD44 v4 and CD44 v6 epitopes stimulate myelopoiesis (***CD44*** v4 and ***CD44*** v6) and lymphopoiesis (***CD44*** v6). In the bone marrow cell population, CD44 v4 and CD44 v6 epitopes are found virtually exclusively on double-positive bone marrow macrophages. The anti- ***CD44*** v4 and v6 ***antibodies*** act on bone marrow macrophages to stimulate granulocyte-macrophage colony-stimulating factor (GM-CSF) production (v4 and v6) and interleukin-6 (IL-6) production (v6). This profile of cytokine production explains the differential stimulation of hemopoiesis by the 2 ***antibodies*** . We suggest that the ***antibodies*** mimic ligand(s) that stimulate GM-CSF or IL-6 production by bone marrow-derived macrophages by binding to CD44 family members that bear CD44 v4 and ***CD44*** v6 epitopes on these cells.
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: ***CD44*** v4 epitope...
... ***CD44*** v6 epitope...

... ***CD44*** variant-specific antibodies

10/KWIC/5 (Item 1 from file: 73)
DIALOG(R)File 73:(c) 2007 Elsevier B.V. All rts. reserv.

TNF-alpha increases the carbohydrate sulfation of CD44: Induction of 6-sulfo N-acetyl lactosamine on N- and O-linked glycans

CD44 and sulfation have both been implicated in leukocyte adhesion. In monocytes, the inflammatory cytokine tumor necrosis factor alpha (TNF-alpha) stimulates CD44 sulfation, and this correlates with the induction of ***CD44*** -mediated adhesion events. However, little is known about the sulfation of CD44 or its induction by inflammatory cytokines. We determined that TNF-alpha induces the carbohydrate sulfation of ***CD44*** . ***CD44*** was established as a major sulfated cell surface protein on myeloid cells. In the SR91 myeloid cell line, the majority of CD44 sulfation was attributed to the glycosaminoglycan chondroitin sulfate. However, TNF-alpha stimulation increased ***CD44*** sulfation two- to threefold, largely attributed to the increased sulfation of N- and O-linked glycans on ***CD44*** . Therefore, TNF-alpha induced a decrease in the percentage of CD44 sulfation due to chondroitin sulfate and an increase due to N- and O-linked sulfation...

...induced on N-linked and (to a lesser extent) on O-linked glycans present on ***CD44*** . This demonstrates that ***CD44*** is modified by sulfated carbohydrates in myeloid cells and that TNF-alpha modifies both the type and amount of carbohydrate sulfation occurring on ***CD44*** . In addition, it demonstrates that TNF-alpha can induce the expression of 6-sulfo N-acetyl glucosamine on both N- and O-linked glycans of CD44 in myeloid cells.
DRUG DESCRIPTORS:
*tumor necrosis factor alpha; *Hermes antigen--endogenous compound --ec; *n acetylglucosamine--endogenous compound--ec; *glycan derivative --endogenous compound--ec
MEDICAL DESCRIPTORS:
sulfation; bone marrow cell; bone marrow culture; cell stimulation; antibody detection; protein modification; leukocyte adherence; protein glycosylation; human; controlled study; human cell; article; priority journal
2002

10/KWIC/6 (Item 1 from file: 155)
DIALOG(R)File 155:(c) format only 2007 Dialog. All rts. reserv.

... ***2002*** ,
... percentage of cells forming focal adhesion-positive lamellae. These effects are prevented by blocking RHAMM antibodies and mimicked by ***agonist*** RHAMM ***antibodies*** . Src-/- fibroblasts exhibit a limited response to PMA but do not increase motility or disassemble...
; Animals; Antibodies--pharmacology--PD; Antigens, CD44--metabolism --ME; Cell Adhesion--drug effects--DE; Cell Line; Cell Movement--drug effects--DE; Extracellular...
Chemical Name: Antibodies; Antigens, CD44; Extracellular Matrix Proteins; Phorbol Esters; hyaluronan-mediated motility receptor; Vinculin; Hyaluronic Acid; src-Family Kinases

10/KWIC/7 (Item 2 from file: 155)
DIALOG(R)File 155:(c) format only 2007 Dialog. All rts. reserv.

... ***2002*** ,
... cell-mediated antitumor response could be elicited by intravenous administration of tumor-derived peptide and agonistic anti-CD40 ***antibody*** or viral immunization and reimmunization. Thus, in this model, tumor growth promotes activation of high...
; Adoptive Transfer; Animals; Antibodies, Monoclonal--immunology--IM; Antigens, CD40--immunology--IM; Antigens, CD44--immunology--IM; Antigens, CD44--metabolism--ME; Antigens, Tumor-Associated, Carbohydrate--administration and dosage--AD; Antigens, Tumor-Associated, Carbohydrate--immunology...
Chemical Name: Antibodies, Monoclonal; Antigens, CD40; Antigens, CD44; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate

10/KWIC/8 (Item 3 from file: 155)
DIALOG(R)File 155:(c) format only 2007 Dialog. All rts. reserv.

... ***2002*** ,
...detected in organs with predominant Mphi2 cells, such as placenta, and in interleukin-4/glucocorticoid- ***stimulated*** Mphi2 cells in vitro. A polyclonal antibody made against human recombinant stabilin-1 confirmed the expression of stabilin-1 protein in splenic...
Descriptors: *Antigens, CD44--chemistry--CH; *Cell Adhesion Molecules, Neuronal--chemistry--CH; Amino Acid Sequence; Animals; Antigens, CD44--genetics--GE; Base Sequence; Cell Adhesion Molecules, Neuronal --genetics--GE; Cloning, Molecular; DNA Primers; Fluorescent...
Chemical Name: Antigens, CD44; Cell Adhesion Molecules, Neuronal; DNA Primers; Receptors, Lymphocyte Homing; STAB1 protein, human; STAB2 protein, human...
? t s10/7/4

10/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16748101 BIOSIS NO.: 200200341612
CD44 variant-specific antibodies trigger hemopoiesis by selective release of cytokines from bone marrow macrophages
AUTHOR: Khaldoyanidi Sophia; Karakhanova Svetlana; Sleeman Jonathan; Herrlich Peter; Ponta Helmut (Reprint)
AUTHOR ADDRESS: Institute of Toxicology and Genetics, Forschungszentrum Karlsruhe, D-76021, Karlsruhe, Germany**Germany
JOURNAL: Blood 99 (11): p3955-3961 June 1, 2002 2002
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Hemopoiesis is regulated by the complex interplay between the bone marrow microenvironment and hemopoietic stem cells and progenitors. The local production of cytokines plays a critical role in this process. Using long-term bone marrow cultures, we show here that monoclonal antibodies directed against the CD44 v4 and CD44 v6 epitopes stimulate myelopoiesis (CD44 v4 and CD44 v6) and lymphopoiesis (***CD44*** v6). In the bone marrow cell population, CD44 v4 and CD44 v6 epitopes are found virtually exclusively on double-positive bone marrow macrophages. The anti- ***CD44*** v4 and v6 antibodies act on bone marrow macrophages to stimulate granulocyte-macrophage colony-stimulating factor (GM-CSF) production (v4 and v6) and interleukin-6 (IL-6) production (v6). This profile of cytokine production explains the differential ***stimulation*** of hemopoiesis by the 2 ***antibodies*** . We suggest that the antibodies mimic ligand(s) that stimulate GM-CSF or IL-6 production by bone marrow-derived macrophages by binding to CD44 family members that bear CD44 v4 and CD44 v6 epitopes on these cells.

```
? ds

Set     Items   Description
S1        179   E1-E7
S2         43   S1 AND (CD44 OR HCAM OR PGP(W)1 OR HEREMES OR HCELL)
S3         43   S1 AND (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL)
S4         26   RD S3  (unique items)
S5          0   S4 AND AGONIST?(20N)(ANTIBOD? OR IMMUNOGLOBULIN?)
S6        305   (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL) AND (AGONIST?
                OR STIMULAT?)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?)
S7        291   (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL) AND (AGONIST?
                OR STIMULAT?)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?(10N)(GLYCAN? OR
                 SACCHARIDE? OR CARBOHYDRATE? OR CHO))
S8        160   RD S7  (unique items)
S9          8   S8 AND PY=2002
S10         8   RD S9  (unique items)
? s s8 and py=2001
            160  S8
        2338551  PY=2001
    S11      10  S8 AND PY=2001
? rd s11
    S12      10  RD S11  (unique items)
? t s12/7/all

 12/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.
```

16407485 BIOSIS NO.: 200200000996

beta1-Integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids

AUTHOR: Casey Rachael C; Burleson Kathryn M; Skubitz Keith M; Pambuccian Stefan E; Oegema Theodore R Jr; Ruff Laura E; Skubitz Amy P N (Reprint)
AUTHOR ADDRESS: Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN, 55455, USA** USA

JOURNAL: American Journal of Pathology 159 (6): p2071-2080 December, 2001
2001
MEDIUM: print
ISSN: 0002-9440
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Ovarian carcinoma multicellular spheroids are an in vitro model of micrometastasis whose adhesive abilities have not been elucidated. In this study, we identified adhesion molecules that mediate the formation of ovarian carcinoma spheroids and their subsequent adhesion to extracellular matrix proteins. The NIH: OVCAR5, but not the SKOV3, ovarian carcinoma cell line formed spheroids similar to multicellular aggregates isolated from patient ascitic fluid. NIH:OVCAR5 spheroid formation was augmented by a beta1-integrin-stimulating monoclonal antibody or exogenous fibronectin, but was inhibited by blocking monoclonal antibodies against the alpha5- or beta1-integrin subunits. By immunohistochemical staining, alpha2-, alpha3-, alpha5-, alpha6-, and beta1-integrin subunits, CD44, and fibronectin were detected in NIH:OVCAR5 spheroids. NIH:OVCAR5 spheroids adhered to fibronectin, laminin, and type IV collagen, and this adhesion was partially inhibited by blocking antibodies against the alpha5-, alpha6-, and alpha2- integrin subunits, respectively. A blocking monoclonal antibody against the beta1-integrin subunit completely inhibited adhesion of the spheroids to all three proteins. These results suggest that interactions between the alpha5beta1-integrin and fibronectin mediate the formation of ovarian carcinoma spheroids and that their adhesion to extracellular matrix proteins at sites of secondary tumor growth may be mediated by a complex interaction between multiple integrins and their ligands.

12/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16369562 BIOSIS NO.: 200100541401
Hyaluronan-independent adhesion of CD44H+ and CD44v10+ lymphocytes to dermal microvascular endothelial cells and keratinocytes
AUTHOR: Weimann Tatjana K; Wagner Christine; Funk Renate; Hirche Herbert; Goos Manfred; Wagner Stephan N (Reprint)
AUTHOR ADDRESS: Department of Dermatology, Hautklinik, Universitaetsklinikum Essen, Hufelandstr. 55, D-45122, Essen, Germany** Germany
JOURNAL: Journal of Investigative Dermatology 117 (4): p949-957 October, 2001 2001
MEDIUM: print
ISSN: 0022-202X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: We have recently shown the CD44 variant isoform 10 (CD44v10) to be expressed on reactive as well as malignant cutaneous lymphocytes; however, the functional consequences of CD44v10 expression on lymphocytes are not elucidated. By using appropriately transfected lymphatic cells we analyzed the role of CD44v10 on lymphocytes in cell-matrix adhesion and homotypic and heterotypic cell-cell adhesion assays. Despite a low binding affinity to hyaluronan, CD44v10-expressing lymphocytes exhibited heterotypic cell-cell adhesion to inflamed dermal microvascular endothelium and keratinocytes, as indicated by Stamper-Woodruff assays on tissue sections of delayed type hypersensitivity reactions and adhesion assays with cultured keratinocytes and cytokine-stimulated human dermal microvascular endothelial cells. ***Antibody*** -blocking assays excluded interaction of CD44v10 with the principal CD44 ligand hyaluronan as well as involvement of selectins or integrins in these heterotypic cell-cell adhesion assays. In contrast, cellular aggregation assays with fluorescence-labeled CD44v10- and CD44H-expressing lymphocytes revealed homotypic CD44v10/CD44v10 binding as well as binding of CD44v10 with CD44H. Heterotypic cell-cell adhesion assays with ultraviolet-A-irradiated CD44v-negative cytokine-stimulated endothelial

cells demonstrated binding kinetics of CD44v10-expressing lymphocytes paralleling those of endothelial CD44H expression. These results imply that a hyaluronan-independent CD44v10/CD44H-mediated pathway is involved in lymphocyte infiltration into the dermis and epidermis of inflamed skin and suggest modulation of CD44H expression on inflamed dermal microvascular endothelium as a mechanism of ultraviolet-A-induced therapeutic effects on the skin.

12/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16298541 BIOSIS NO.: 200100470380
Hyaluronic acid increases motility/intracellular CA2+ concentration in human sperm in vitro
AUTHOR: Bains R; Miles D M; Carson R J (Reprint); Adeghe J
AUTHOR ADDRESS: School of Health Sciences, University of Wolverhampton, 62-68 Lichfield Street, Wolverhampton, WV1 1DJ, UK**UK
JOURNAL: Archives of Andrology 47 (2): p119-125 April-June, 2001
2001
MEDIUM: print
ISSN: 0148-5016
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: This study investigated the mechanisms of the stimulatory effect of hyaluronic acid on motility in human sperm in vitro. A method, involving the measurement of forward progression through an agarose gel, was used to measure sperm motility quantitatively. Changes in intracellular Ca2+ concentrations in sperm were detected using the fluorescent dye Fluo-3. The effects of hyaluronic acid (6.5, 65, 650 ng/mL) and nifedipine (32 nM) on sperm motility were investigated. The effects of hyaluronic acid, nifedipine (32 nM), A23187 (32 muM), and a monoclonal antibody to human CD44 (1 mug/mL) on changes in intracellular CA2+ concentrations were investigated. Hyaluronic acid significantly ($p < .008$) stimulated sperm motility and this was partially inhibited by nifedipine. A23187 significantly ($p < .005$) increased intracellular CA2+ concentrations. Hyaluronic acid significantly ($p < .04$) increased intracellular Ca2+ concentrations and this was inhibited by nifedipine and a monoclonal ***antibody*** to human ***CD44*** . Hyaluronic acid stimulated human sperm motility by increasing Ca2+ concentration, partially via an influx of extracellular Ca2+.

12/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

15956776 BIOSIS NO.: 200100128615
Constitutive intracellular expression and activation-induced cell surface up-regulation of CD44v3 in human T lymphocytes
AUTHOR: Forster-Horvath Csaba; Bocsi Jozsef; Raso Erzsebet; Orban Tamas I; Olah Edith; Timar Jozsef; Ladanyi Andrea (Reprint)
AUTHOR ADDRESS: Department of Tumor Progression, National Institute of Oncology, Rath Gy. u. 7-9, Budapest, H-1122, Hungary**Hungary
JOURNAL: European Journal of Immunology 31 (2): p600-608 February, 2001
2001
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The cell adhesion molecule CD44 exists in multiple isoforms generated by alternative RNA splicing. Increased expression of ***CD44*** isoforms containing exon v6 and v9 has been reported to be associated with the activated state of T lymphocytes. Using monoclonal antibodies against variant exon products we studied the expression of another variant exon, v3 on resting and in vitro activated human peripheral blood T cells. We found that CD44v3, in parallel with CD44v6, is up-regulated at the surface of normal T cells stimulated by anti-CD3 antibody or by the phorbol ester PMA, as well as on PMA-stimulated T cell leukemia lines CCRF-CEM and MOLT-4. Beside the cell surface, we demonstrated CD44v3 intracellularly in both resting and activated T cells by flow cytometry and immunomorphology. Reverse transcription-PCR and Western blot analyses confirmed the constitutive expression of CD44v3 in these cells. The increase in the cell surface expression of CD44v3 on stimulated T lymphocytes was inhibited by cycloheximide and brefeldin A, indicating the requirement of de novo protein synthesis and endoplasmic reticulum Golgi transport. Our studies establish CD44v3 as an additional activation marker for human T cells, with a yet unidentified function.

12/7/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2007 Elsevier B.V. All rts. reserv.

11365463 EMBASE No: 2001379677
Hyaluronan-independent adhesion of CD44HSUP+ and CD44v10SUP+ lymphocytes to dermal microvascular endothelial cells and keratinocytes
Weimann T.K.; Wagner C.; Funk R.; Hirche H.; Goos M.; Wagner S.N.
Dr. S.N. Wagner, Department of Dermatology, Hautklinik, Universitatsklinikum Essen, Hufelandstr. 55, D-45122 Essen Germany
AUTHOR EMAIL: stephan.wagner@uni-essen.de
Journal of Investigative Dermatology (J. INVEST. DERMATOL.) (United States) 2001, 117/4 (949-957)
CODEN: JIDEA ISSN: 0022-202X
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 50

We have recently shown the CD44 variant isoform 10 (CD44v10) to be expressed on reactive as well as malignant cutaneous lymphocytes; however, the functional consequences of CD44v10 expression on lymphocytes are not elucidated. By using appropriately transfected lymphatic cells we analyzed the role of CD44v10 on lymphocytes in cell-matrix adhesion and homotypic and heterotypic cell-cell adhesion assays. Despite a low binding affinity to hyaluronan, CD44v10-expressing lymphocytes exhibited heterotypic cell-cell adhesion to inflamed dermal microvascular endothelium and keratinocytes, as indicated by Stamper-Woodruff assays on tissue sections of delayed type hypersensitivity reactions and adhesion assays with cultured keratinocytes and cytokine-stimulated human dermal microvascular endothelial cells. ***Antibody*** -blocking assays excluded interaction of CD44v10 with the principal CD44 ligand hyaluronan as well as involvement of selectins or integrins in these heterotypic cell-cell adhesion assays. In contrast, cellular aggregation assays with fluorescence- labeled CD44v10- and CD44H-expressing lymphocytes revealed homotypic CD44v10/CD44v10 binding as well as binding of CD44v10 with CD44H. Heterotypic cell-cell adhesion assays with ultraviolet- A-irradiated CD44v-negative cytokine-stimulated endothelial cells demonstrated binding kinetics of CD44v10-expressing lymphocytes paralleling those of endothelial CD44H expression. These results imply that a hyaluronan-independent CD44v10/CD44H-mediated pathway is involved in lymphocyte infiltration into the dermis and epidermis of inflamed skin and suggest modulation of CD44H expression on inflamed dermal microvascular endothelium as a mechanism of ultraviolet-A-induced therapeutic effects on the skin.

12/7/6 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2007 Elsevier B.V. All rts. reserv.

11292955 EMBASE No: 2001308583
Hyaluronic acid increases motility/intracellular CaSUP2+ concentration in human sperm in vitro
Bains R.; Miles D.M.; Carson R.J.; Adeghe J.
Dr. R.J. Carson, School of Health Sciences, University of Wolverhampton, 62-68 Lichfield Street, Wolverhampton WV1 1DJ United Kingdom
AUTHOR EMAIL: R.J.Carson@wlv.ac.uk
Archives of Andrology (ARCH. ANDROL.) (United States) 2001, 47/2 (119-125)
CODEN: ARAND ISSN: 0148-5016
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 18

This study investigated the mechanisms of the stimulatory effect of hyaluronic acid on motility in human sperm in vitro. A method, involving the measurement of forward progression through an agarose gel, was used to measure sperm motility quantitatively. Changes in intracellular CaSUP2+ concentrations in sperm were detected using the fluorescent dye Fluo-3. The effects of hyaluronic acid (6.5, 65, 650 ng/mL) and nifedipine (32 nM) on sperm motility were investigated. The effects of hyaluronic acid, nifedipine (32 nM), A23187 (32 muM), and a monoclonal antibody to human CD44 (1 mug/mL) on changes in intracellular CASUP2+ concentrations were investigated. Hyaluronic acid significantly ($p < .008$) stimulated sperm motility and this was partially inhibited by nifedipine. A23187 significantly ($p < .005$) increased intracellular CASUP2+ concentrations. Hyaluronic acid significantly ($p < .04$) increased intracellular CaSUP2+ concentrations and this was inhibited by nifedipine and a monoclonal ***antibody*** to human ***CD44*** . Hyaluronic acid ***stimulated*** human sperm motility by increasing intracellular CaSUP2+ concentration, partially via an influx of extracellular CaSUP2+.

12/7/7 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2007 Elsevier B.V. All rts. reserv.

11087244 EMBASE No: 2001104096
Combining G-CSF with a blockade of adhesion strongly improves the reconstitutive capacity of mobilized hematopoietic progenitor cells
Christ O.; Kronenwett R.; Haas R.; Zoller M.
Dr. M. Zoller, Department of Tumor Progression, Immune Defense, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg Germany
AUTHOR EMAIL: m.zoeller@dkfz.de
Experimental Hematology (EXP. HEMATOL.) (United States) 2001, 29/3 (380-390)
CODEN: EXHEB ISSN: 0301-472X
PUBLISHER ITEM IDENTIFIER: S0301472X00006743
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 48

Objective. Mobilization of hematopoietic progenitor cells is achieved mainly by application of growth factors and, more recently, by blockade of adhesion. In this report, we describe the advantages of a combined treatment with granulocyte colony-stimulating factor (G-CSF) and anti-VLA4

(CD49d)/anti-CD44 as compared to treatment with the individual components .Materials and Methods. Mobilization by intravenous injection of anti-CD44, anti-VLA4, or G-CSF was controlled in spleen and bone marrow with regard to frequencies of multipotential colony-forming unit (C-CFU), marrow repopulating ability, long-term reconstitution, recovery of myelopoiesis, and regain of immunocompetence. Results. Mobilization by anti-CD44 had a strong effect on expansion of early progenitor cells in the bone marrow, while the recovery in the spleen was poor. In anti-CD49d-mobilized noncommitted and committed progenitors, progenitor expansion was less pronounced, but settlement in the spleen was quite efficient. Thus, anti- ***CD44*** and anti-CD49d differently influenced mobilization. Accordingly, mobilization and recovery after transfer were improved by combining anti- ***CD44*** with anti-CD49d treatment. Mobilization by G-CSF was most efficient with respect to recovery of progenitor cells in the spleen. However, when transferring G-CSF-mobilized cells, regain of immunocompetence was strongly delayed. This disadvantage could be overridden when progenitor cells were mobilized via blockade of adhesion and when expansion of these mobilized progenitor cells was supported by low-dose G-CSF only during the last 24 hours before transfer.Conclusion. Mobilization of pluripotent progenitor cells via antibody blockade of CD44 or CD49d or via G-CSF relies on distinct mechanisms. Therefore, the reconstitutive capacity of a transplant can be significantly improved by mobilization regimens combining antibody with low-dose G-CSF treatment. Copyright (c) 2001 International Society for Experimental Hematology.

12/7/8 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2007 Elsevier B.V. All rts. reserv.

11086516 EMBASE No: 2001102999
Most parasite-specific CD8SUP+ cells in Trypanosoma cruzi-infected chronic mice are down-regulated for T-cell receptor-alphabeta and CD8 molecules
Grisotto M.G.; D'Imperio Lima M.R.; Marinho C.R.F.; Tadokoro C.E.; Abrahamsohn I.A.; Alvarez J.M.
Dr. J.M. Alvarez, Departamento de Imunologia, ICB IV, Universidade de Sa(tilde)o Paulo, Average Professor Lineu Prestes 1730, Sa(tilde)o Paulo, SP, CEP: 05508-900 Brazil
Immunology (IMMUNOLOGY) (United Kingdom) 2001, 102/2 (209-217)
CODEN: IMMUA ISSN: 0019-2805
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 31

The present study shows that CD8SUP+ T lymphocytes expressing low levels of T-cell receptor (TCR)alphabeta, CD8 and CD3 accumulate in the spleen, blood, peritoneum and liver, but not in the lymph nodes of mice chronically infected with Trypanosoma cruzi. Analysis of spleen lymphocytes reveals that most CD8SUPLOW TCRSUPLOW T cells have an experienced phenotype (CD44SUPHIGH CD62LSUPLOW and CD45RA,B,CSUPLOW). These cells have small size, lack activation markers such as CD69, CD25 and CD11b (Mac-1), and do not spontaneously secrete cytokines, suggesting they are at the resting state. When stimulated in vitro with T. cruzi-infected macrophages, TCRSUPLOW CD8SUPLOW T cells behave as parasite-specific memory cells, readily responding with interferon-gamma (IFN-gamma) production. Indeed, among parasite-activated CD8SUP+ lymphocytes, IFN-gamma production was mostly due to TCRSUPLOW CD8SUPLOW cells. Upon in vitro ***stimulation*** with anti-CD3/CD28 monoclonal antibodies, down-regulated cells produce IFN-gamma and tumour necrosis factor-alpha, but not interleukin IL-10 or IL-4. Our results indicate that despite parasite persistence, most T. cruzi-specific experienced CD8SUP+ cells are resting. Nevertheless, when encountering infected macrophages these cells differentiate to Tc1

effectors.

12/7/9 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

13460312 PMID: 11698286
Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities.
Parlato S; Santini S M; Lapenta C; Di Pucchio T; Logozzi M; Spada M; Giammarioli A M; Malorni W; Fais S; Belardelli F
Laboratory of Virology, Laboratory of Ultrastructures, Istituto Superiore di Sanita, Rome, Italy.
Blood (United States) Nov 15 2001, 98 (10) p3022-9, ISSN 0006-4971--Print Journal Code: 7603509
Publishing Model Print
Document type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
The migration capability of dendritic cells (DCs) is regulated by their response to factors, namely chemokines, that characterize maturation stage and shape their functional activities. This study examines the morphology, expression of chemokines/chemokine receptors, and migration properties of DCs generated after treatment of monocytes with type I interferon (IFN) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (IFN-DCs). IFN-DCs showed phenotypical and morphologic features undetectable in DCs generated in the presence of interleukin 4 (IL-4) and GM-CSF, such as expression of CD83 and CD25 and the presence of CD44+, highly polarized, thin, and long dendrites. IFN-DCs markedly migrated in response to beta-chemokines (especially MIP-1beta) and expressed the Th-1 chemokine IP-10. Notably, IFN-DCs showed an up-regulation of CCR7 as well as of its natural ligand MIP-3beta, characteristics typical of mature DCs. Of interest, IFN-DCs exhibited a marked chemotactic response to MIP-3beta in vitro and strong migratory behavior in severe combined immunodeficient (SCID) mice. In SCID mice reconstituted with human peripheral blood leukocytes, IFN-DCs induced a potent primary human antibody response and IFN-gamma production, indicative of a Th-1 immune response. These results define the highly specialized maturation state of IFN-DCs and point out the existence of a "natural alliance" between type I IFN and monocyte/DC development, instrumental for ensuring an efficient connection between innate and adaptive immunity.
Record Date Created: 20011107
Record Date Completed: 20011221

12/7/10 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

13373624 PMID: 11531942
C1q-bearing immune complexes induce IL-8 secretion in human umbilical vein endothelial cells (HUVEC) through protein tyrosine kinase- and mitogen-activated protein kinase-dependent mechanisms: evidence that the 126 kD phagocytic C1q receptor mediates immune complex activation of HUVEC.
Xiao S; Xu C; Jarvis J N
Department of Pedatrics, Rheumatology Research, University of Oklahoma Health Sciences Center and the Children's Hospital of Oklahoma, Oklahoma City, 73104, USA.
Clinical and experimental immunology (England) Sep 2001, 125 (3) p360-7, ISSN 0009-9104--Print Journal Code: 0057202

Contract/Grant Number: AR-43967; AR; NIAMS
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

Endothelial cells play a pivotal role in the initiation and perpetuation of inflammation. C1q, the first component of the classical pathway of complement, is a potent stimulus leading to endothelial cell activation and cytokine production. The specific cellular mechanisms through which endothelial cells are stimulated by C1q are not known. We stimulated human umbilical vein endothelial cells (HUVEC) with either monomeric C1q or C1q-bearing immune complexes (C1q-IC) in the presence or absence of inhibitors of protein tyrosine kinases (PTK) or mitogen-activated protein kinases (MAPK). C1q-IC, but not monomeric C1q, induced IL-8 production in dose- and time-dependent fashion. R3, a cross-linking monoclonal IgM antibody against the 126 kD phagocytic C1q receptor (C1qR), also ***stimulated*** IL-8 production. IL-8 mRNA accumulation was detected by Northern blot analysis within 2 h of stimulation by the immune complexes and was enhanced by the addition of cycloheximide. Secretion of IL-8 by C1q-IC stimulated HUVEC was completely blocked by the PTK inhibitor, genistein or the MAPK inhibitor, UO126. These experiments demonstrate that C1q-IC-induced production of IL-8 in HUVEC is dependent upon the activation of PTK and MAPK. These findings also support a role for the phagocytic C1qR as an important activator of HUVEC by immune complexes.

Record Date Created: 20010904
Record Date Completed: 20011011

```
? ds

Set     Items   Description
S1        179   E1-E7
S2         43   S1 AND (CD44 OR HCAM OR PGP(W)1 OR HEREMES OR HCELL)
S3         43   S1 AND (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL)
S4         26   RD S3  (unique items)
S5          0   S4 AND AGONIST?(20N)(ANTIBOD? OR IMMUNOGLOBULIN?)
S6        305   (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL) AND (AGONIST?
                OR STIMULAT?)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?)
S7        291   (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL) AND (AGONIST?
                OR STIMULAT?)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?(10N)(GLYCAN? OR
                SACCHARIDE? OR CARBOHYDRATE? OR CHO))
S8        160   RD S7  (unique items)
S9          8   S8 AND PY=2002
S10         8   RD S9  (unique items)
S11        10   S8 AND PY=2001
S12        10   RD S11  (unique items)
? s s8 and agonist?(5n)(antibod? or immunoglobulin?)(5n)(cd44 or hermes or pgp(w)1
or hcam or hcell)
Processing
          160   S8
       562028   AGONIST?
      2252588   ANTIBOD?
       838135   IMMUNOGLOBULIN?
        22231   CD44
         5997   HERMES
        10314   PGP
     12431632   1
          795   PGP(W)1
          137   HCAM
           36   HCELL
            7   AGONIST?(5N)(ANTIBOD? OR IMMUNOGLOBULIN?)(5N)((((CD44 OR
                HERMES) OR PGP(W)1) OR HCAM) OR HCELL)
S13         6   S8 AND AGONIST?(5N)(ANTIBOD? OR IMMUNOGLOBULIN?)(5N)(CD44
                OR HERMES OR PGP(W)1 OR HCAM OR HCELL)
```

? rd s13
S14 6 RD S13 (unique items)
? t s14/7/all

14/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

11795226 BIOSIS NO.: 199395097492
Activation of CD44 induces ICAM-1/LFA-1-independent, calcium magnesium-independent adhesion pathway in lymphocyte-endothelial cell interaction
AUTHOR: Toyama-Sorimachi Noriko; Miyake Kensuke; Miyasaka Masayuki (Reprint)
AUTHOR ADDRESS: Dep. Immunol., Tokyo Metropolitan Inst. Medical Sci., 3-18-22, Hon-Komagome, Bunkyo, Tokyo, Japan**Japan
JOURNAL: European Journal of Immunology 23 (2): p439-446 1993
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: We have established an endothelial cell line KOP2.16 from pooled mouse lymph nodes. Resting lymphocytes avidly bound to KOP2.16 and migrated underneath the cytoplasm. The binding was partly mediated by VLA-4 and VCAM-1, but apparently independent of CD44 since anti- ***CD44*** antibody examined failed to inhibit the binding. However, pretreatment of lymphocytes with anti-CD44 resulted in a rapid appearance of Ca-2+-, Mg-2+-independent, LFA-1/ICAM-1-, CD2/LFA-3, VLA-4/VCAM-1-independent lymphocyte binding, indicating that a novel adhesion pathway was induced by the anti- ***CD44*** treatment. Interestingly, the elicited adhesion was observed only when anti-CD44 that block hyaluronate recognition of CD44 were used for lymphocyte pretreatment. Neither hyaluronate itself nor non-blocking anti- ***CD44*** up-regulated the adhesion. Fab fragment of the blocking anti-CD44 did not induce the up-regulation unless cross-linked with a second antibody, indicating that cross-linking of surface CD44 is necessary for induction of a novel adhesion pathway. We propose that the agonistic anti-CD44 antibodies induce a novel adhesion pathway by mimicking ligand binding to CD44 on the lymphocyte surface and that non-hyaluronate ligand(s) is involved in regulation of adhesive function of ***CD44*** . Potential involvement of such a regulatory mechanism in lymphocyte homing is discussed.

14/7/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2007 Elsevier B.V. All rts. reserv.

06857462 EMBASE No: 1997140097
CD44: Structure, function, and association with the malignant process
Naor D.; Sionov R.V.; Ish-Shalom D.
D. Naor, LCGTI, Hadassah Medical School, Hebrew University, Jerusalem 91120 Israel
Advances in Cancer Research (ADV. CANCER RES.) (United States) 1997, 71/- (241-319)
CODEN: ACRSA ISSN: 0065-230X
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 468

CD44 is a ubiquitous multistructural and multifunctional cell surface adhesion molecule involved in cell-cell and cell-matrix

interactions. Twenty exons are involved in the genomic organization of this molecule. The first five and the last 5 exons are constant, whereas the 10 extras located between these regions are subjected to alternative splicing, resulting in the generation of a variable region. Differential utilization of the 10 variable region exons, as well as variations in N-glycosylation, O-glycosylation, and glycosaminoglycanation (by heparan sulfate or chondroitin sulfate), generate multiple isoforms (at least 20 are known) of different molecular sizes (85- 230 kDa). The smallest ***CD44*** molecule (85-95 kDa), which lacks the entire variable region, is standard CD44 (CD44s). As it is expressed mainly on cells of lymphohematopoietic origin, CD44s is also known as hematopoietic ***CD44*** (CD44H). CD44s is a single-chain molecule composed of a distal extracellular domain (containing the ligand-binding sites), a membrane-proximal region, a transmembrane-spanning domain, and a cytoplasmic tail. The molecular sequence (with the exception of the membrane-proximal region) displays high interspecies homology. After immunological activation, T lymphocytes and other leukocytes transiently upregulate CD44 isoforms expressing variant exons (designated CD44v). A ***CD44*** isoform containing the last 3 exon products of the variable region (CD44V8-10, also known as epithelial ***CD44*** or CD44E), is preferentially expressed on epithelial cells. The longest CD44 isoform expressing in tandem eight exons of the variable region (CD44V3-10) was detected in keratinocytes. Hyaluronic acid (HA), an important component of the extracellular matrix (ECM), is the principal, but by no means the only, ligand of ***CD44*** . Other ***CD44*** ligands include the ECM components collagen, fibronectin, laminin, and chondroitin sulfate. Mucosal addressin, serglycin, osteopontin, and the class II invariant chain (Ii) are additional, ECM- unrelated, ligands of the molecule. In many, but not in all cases, ***CD44*** does not bind HA unless it is stimulated by phorbol esters, activated by agonistic anti- ***CD44*** ***antibody*** , or deglycosylated (e.g., by tunicamycin). CD44 is a multifunctional receptor involved in cell-cell and cell-ECM interactions, cell traffic, lymph node homing, presentation of chemokines and growth factors to traveling cells, and transmission of growth signals. CD44 also participates in the uptake and intracellular degradation of HA, as well as in transmission of signals mediating hematopoiesis and apoptosis. Many cancer cell types as well as their metastases express high levels of ***CD44*** . Whereas some tumors, such as gliomas, exclusively express standard CD44, other neoplasms, including gastrointestinal cancer, bladder cancer, uterine cervical cancer, breast cancer and non-Hodgkin's lymphomas, also express ***CD44*** variants. Hence ***CD44*** , particularly its variants, may be used as diagnostic or prognostic markers of at least some human malignant diseases. Furthermore, it has been shown in animal models that injection of reagents interfering with ***CD44*** -ligand interaction (e.g., CD44s- or CD44v-specific antibodies) inhibit local tumor growth and metastatic spread. These findings suggest that CD44 may confer a growth advantage on some neoplastic cells and, therefore, could be used as a target for cancer therapy. It is hoped that identification of CD44 variants expressed on cancer but not on normal cells will lead to the development of anti-CD44 reagents restricted to the neoplastic growth.

14/7/3 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2007 Elsevier B.V. All rts. reserv.

05306990 EMBASE No: 1993075075
Activation of CD44 induces ICAM-1/LFA-1-independent, Casup 2sup +, Mgsup 2sup +-independent adhesion pathway in lymphocyte-endothelial cell interaction
Toyama-Sorimachi N.; Miyake K.; Miyasaka M.
Department of Immunology, Tokyo Metropol Inst Medical Science, 3-18-22 Hon-Komagome,Bunkyo, Tokyo Japan
European Journal of Immunology (EUR. J. IMMUNOL.) (Germany) 1993, 23/2

(439-446)
CODEN: EJIMA ISSN: 0014-2980
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

We have established an endothelial cell line KOP2.16 from pooled mouse lymph nodes. Resting lymphocytes avidly bound to KOP2.16 and migrated underneath the cytoplasm. The binding was partly mediated by VLA-4 and VCAM-1, but apparently independent of CD44 since anti-CD44 antibody examined failed to inhibit the binding. However, pretreatment of lymphocytes with anti-CD44 resulted in the rapid appearance of Casup 2sup +-, Mgsup 2sup +-independent, LFA-1/ICAM-1-, CD2/LFA-3, VLA-4/VCAM-1-independent lymphocyte binding, indicating that a novel adhesion pathway was induced by the anti- ***CD44*** treatment. Interestingly, the elicited adhesion was observed only when anti-CD44 that block hyaluronate recognition of CD44 were used for lymphocyte pretreatment. Neither hyaluronate itself nor non-blocking anti- ***CD44*** up-regulated the adhesion. Fab fragment of the blocking anti- ***CD44*** did not induce the up-regulation unless cross-linked with a second antibody, indicating that cross-linking of surface CD44 is necessary for induction of a novel adhesion pathway. We propose that the ***agonistic*** anti-CD44 antibodies induce a novel adhesion pathway by mimicking ligand binding to CD44 on the lymphocyte surface and that non-hyaluronate ligand(s) is involved in regulation of adhesive function of ***CD44*** . Potential involvement of such a regulatory mechanism in lymphocyte homing is discussed.

14/7/4 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

22729437 PMID: 16949761
Potential roles for hyaluronan and CD44 in kainic acid-induced mossy fiber sprouting in organotypic hippocampal slice cultures.
Bausch S B
Department of Pharmacology, Uniformed Services University, Room C2007, 4301 Jones Bridge Road, Bethesda, MD 20814-4799, USA. sbausch@usuhs.mil
Neuroscience (United States) Nov 17 2006, 143 (1) p339-50, ISSN 0306-4522--Print Journal Code: 7605074
Contract/Grant Number: NS042346; NS; NINDS
Publishing Model Print-Electronic
Document type: In Vitro; Journal Article; Research Support, N.I.H., Extramural
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
The most well-documented synaptic rearrangement associated with temporal lobe epilepsy is mossy fiber sprouting (MFS). MFS is a pronounced expansion of granule cell mossy fiber axons into the inner dentate molecular layer. The recurrent excitatory network formed by MFS is hypothesized to play a critical role in epileptogenesis, which is the transformation of the normal brain into one that is prone to recurrent spontaneous seizures. While many studies have focused on the functional consequences of MFS, relatively few have investigated the molecular mechanisms underlying the increased propensity of mossy fibers to invade the inner molecular layer. We hypothesized that changes in two components of the extracellular matrix, hyaluronan and its primary receptor, ***CD44*** , contribute to MFS. Hyaluronan contributes to laminar-specificity in the hippocampus and increases in hyaluronan and CD44 are associated with temporal lobe epilepsy. We tested our hypothesis in an in vitro model of MFS using a combination of histological and biochemical approaches. Application of kainic acid (KA) to organotypic hippocampal slice cultures induced robust MFS into the inner dentate molecular layer compared with vehicle-treated

controls. Degradation of hyaluronan with hyaluronidase significantly reduced but did not eliminate KA-induced MFS, suggesting that hyaluronan played a permissive role in MFS, but that loss of hyaluronan signaling alone was not sufficient to block mossy fiber reorganization. Comparison of CD44 expression with MFS revealed that when CD44 expression in the molecular layers was high, MFS was minimal and when CD44 expression/function was reduced following KA treatment or with function blocking antibodies, MFS was increased. The time course of KA-induced reductions in CD44 expression was identical to the temporal progression of KA-induced MFS reported previously in hippocampal slice cultures, suggesting that reduced CD44 expression may help promote MFS. Understanding the molecular mechanisms underlying MFS may lead to therapeutic interventions that limit epileptogenesis.

Record Date Created: 20061107
Record Date Completed: 20070126
Date of Electronic Publication: 20060901

14/7/5 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

09595007 PMID: 7679645

Activation of CD44 induces ICAM-1/LFA-1-independent, Ca2+, Mg(2+)-independent adhesion pathway in lymphocyte-endothelial cell interaction.

Toyama-Sorimachi N; Miyake K; Miyasaka M
Department of Immunology, Tokyo Metropolitan Institute of Medical Science, Japan.

European journal of immunology (GERMANY) Feb 1993, 23 (2) p439-46, ISSN 0014-2980--Print Journal Code: 1273201
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

We have established an endothelial cell line KOP2.16 from pooled mouse lymph nodes. Resting lymphocytes avidly bound to KOP2.16 and migrated underneath the cytoplasm. The binding was partly mediated by VLA-4 and VCAM-1, but apparently independent of CD44 since anti-CD44 antibody examined failed to inhibit the binding. However, pretreatment of lymphocytes with anti-CD44 resulted in the rapid appearance of Ca(2+)-, Mg(2+)-independent, LFA-1/ICAM-1-, CD2/LFA-3, VLA-4/VCAM-1-indepen dent lymphocyte binding, indicating that a novel adhesion pathway was induced by the anti- ***CD44*** treatment. Interestingly, the elicited adhesion was observed only when anti-CD44 that block hyaluronate recognition of ***CD44*** were used for lymphocyte pretreatment. Neither hyaluronate itself nor non-blocking anti-CD44 up-regulated the adhesion. Fab fragment of the blocking anti- ***CD44*** did not induce the up-regulation unless cross-linked with a second antibody, indicating that cross-linking of surface CD44 is necessary for induction of a novel adhesion pathway. We propose that the ***agonistic*** anti- ***CD44*** antibodies induce a novel adhesion pathway by mimicking ligand binding to CD44 on the lymphocyte surface and that non-hyaluronate ligand(s) is involved in regulation of adhesive function of ***CD44*** . Potential involvement of such a regulatory mechanism in lymphocyte homing is discussed.

Record Date Created: 19930322
Record Date Completed: 19930322

14/7/6 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

127306021 CA: 127(22)306021a JOURNAL
Heregulin and agonistic anti-p185c-erbB2 antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185c-erbB2: increased invasiveness may contribute to poor prognosis
AUTHOR(S): Xu, Feng-Ji; Stack, Sharon; Boyer, Cinda; O'Briant, Kathy; Whitaker, Regina; Mills, Gordon B.; Yu, Yin Hua; Bast, Robert C., Jr.
LOCATION: Division of Medicine, M. D. Anderson Cancer Center, University of Texas, Houston, TX, 77030, USA
JOURNAL: Clin. Cancer Res. DATE: 1997 VOLUME: 3 NUMBER: 9 PAGES: 1629-1634 CODEN: CCREF4 ISSN: 1078-0432 LANGUAGE: English PUBLISHER: American Association for Cancer Research
SECTION:
CA214001 Mammalian Pathological Biochemistry
CA201XXX Pharmacology
CA202XXX Mammalian Hormones
CA215XXX Immunochemistry
CA263XXX Pharmaceuticals
IDENTIFIERS: heregulin p185cerbB2 antibody breast cancer
DESCRIPTORS:
Antibodies... Breast tumors... Cell proliferation... Heregulins...
heregulin and agonistic anti-p185c-erbB2 antibody inhibition of proliferation and increase of invasiveness of breast cancer overexpressing p185c-erbB2
CD44(antigen)... ICAM-1(cell adhesion molecule)... Immunotherapy...
Immunotoxins... Phosphorylation(biological)...
heregulin and agonistic anti-p185c-erbB2 antibody inhibition of proliferation and increase of invasiveness of breast cancer overexpressing p185c-erbB2 in relation to
neu(receptor)...
p185neu; heregulin and agonistic anti-p185c-erbB2 antibody inhibition of proliferation and increase of invasiveness of breast cancer overexpressing p185c-erbB2
CAS REGISTRY NUMBERS:
146480-36-6 heregulin and agonistic anti-p185c-erbB2 antibody inhibition of proliferation and increase of invasiveness of breast cancer overexpressing p185c-erbB2 in relation to
? ds

Set	Items	Description
S1	179	E1-E7
S2	43	S1 AND (CD44 OR HCAM OR PGP(W)1 OR HEREMES OR HCELL)
S3	43	S1 AND (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL)
S4	26	RD S3 (unique items)
S5	0	S4 AND AGONIST?(20N)(ANTIBOD? OR IMMUNOGLOBULIN?)
S6	305	(CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL) AND (AGONIST? OR STIMULAT?)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?)
S7	291	(CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL) AND (AGONIST? OR STIMULAT?)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?(10N)(GLYCAN? OR SACCHARIDE? OR CARBOHYDRATE? OR CHO))
S8	160	RD S7 (unique items)
S9	8	S8 AND PY=2002
S10	8	RD S9 (unique items)
S11	10	S8 AND PY=2001
S12	10	RD S11 (unique items)
S13	6	S8 AND AGONIST?(5N)(ANTIBOD? OR IMMUNOGLOBULIN?)(5N)(CD44 OR HERMES OR PGP(W)1 OR HCAM OR HCELL)
S14	6	RD S13 (unique items)

?

```
Set      Items   Description
S1         179   E1-E7
S2          43   S1 AND (CD44 OR HCAM OR PGP(W)1 OR HEREMES OR HCELL)
S3          43   S1 AND (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL)
S4          26   RD S3  (unique items)
S5           0   S4 AND AGONIST?(20N)(ANTIBOD? OR IMMUNOGLOBULIN?)
S6         305   (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL) AND (AGONIST?
              OR STIMULAT?)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?)
S7         291   (CD44 OR HCAM OR PGP(W)1 OR HERMES OR HCELL) AND (AGONIST?
              OR STIMULAT?)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?(10N)(GLYCAN? OR
               SACCHARIDE? OR CARBOHYDRATE? OR CHO))
S8         160   RD S7  (unique items)
S9           8   S8 AND PY=2002
S10          8   RD S9  (unique items)
S11         10   S8 AND PY=2001
S12         10   RD S11  (unique items)
S13          6   S8 AND AGONIST?(5N)(ANTIBOD? OR IMMUNOGLOBULIN?)(5N)(CD44 -
              OR HERMES OR PGP(W)1 OR HCAM OR HCELL)
S14          6   RD S13  (unique items)
S15          7   AGONIST?(5N)(ANTIBOD? OR IMMUNOGLOBULIN?)(5N)(CD44 OR HERM-
              ES OR PGP(W)1 OR HCAM OR HCELL)
S16          6   RD S15  (unique items)
? t s24/3/all
>>>Set 24 does not exist
? t s4/3/all

 4/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

0019598938   BIOSIS NO.: 200700258679
CD15 (Lewis x) expression in human myeloid cell differentiation is
  regulated by sialidase activity.
AUTHOR: Gadhoum Samah Z (Reprint); Sackstein Robert
AUTHOR ADDRESS: Brigham and Womens Hosp, Harvard Skin Dis Res Ctr, Dept
  Dermatol, Boston, MA USA**USA
JOURNAL: Blood  108 (11, Part 1): p546A-547A NOV 16 2006 2006
CONFERENCE/MEETING: 48th Annual Meeting of the
American-Society-of-Hematology  Orlando, FL, USA  December 09 -12, 2006;
20061209
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English


 4/3/2     (Item 2 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

0019598682   BIOSIS NO.: 200700258423
HCELL is the major E- and L-selectin ligand expressed on human
  hematopoietic progenitor cells and colon carcinoma cells.
AUTHOR: Chu Julia T (Reprint); Burdick Monica M; Sackstein Robert
AUTHOR ADDRESS: Brigham and Womens Hosp, Dept Med, Boston, MA 02115 USA**
  USA
JOURNAL: Blood  108 (11, Part 1): p477A-478A NOV 16 2006 2006
CONFERENCE/MEETING: 48th Annual Meeting of the
American-Society-of-Hematology  Orlando, FL, USA  December 09 -12, 2006;
20061209
SPONSOR: Amer Soc Hematol
```

ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

4/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

19372124 BIOSIS NO.: 200700031865
G-CSF induces E-selectin ligand expression on human myeloid cells
AUTHOR: Dagia Nilesh M; Gadhoum Samah Z; Knoblauch Christine A; Spencer Joel A; Zamiri Parisa; Lin Charles P; Sackstein Robert (Reprint)
AUTHOR ADDRESS: Harvard Univ, Sch Med, Brigham and Womens Hosp, Dept Dermatol, 77 Ave Louis Pasteur,Room 671, Boston, MA 02115 USA**USA
AUTHOR E-MAIL ADDRESS: rsackstein@rics.bwh.harvard.edu
JOURNAL: Nature Medicine 12 (10): p1185-1190 OCT 2006 2006
ISSN: 1078-8956
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

19252010 BIOSIS NO.: 200600597405
Expression of HCELL confers shear-resistant E- and L-selectin ligand activity on colon carcinoma cells
AUTHOR: Burdick Monica M (Reprint); Chu Julia T; Knoblauch Christine A; Sackstein Robert
AUTHOR ADDRESS: Brigham and Womens Hosp, Boston, MA 02115 USA**USA
JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 47 p801 APR 2006 2006
CONFERENCE/MEETING: 97th Annual Meeting of the American-Association-for-Cancer-Research (AACR) Washington, DC, USA April 01 -05, 2006; 20060401
SPONSOR: Amer Assoc Canc Res
ISSN: 0197-016X
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

4/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

19125608 BIOSIS NO.: 200600471003
HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells
AUTHOR: Burdick Monica M; Chu Julia T; Godar Samuel; Sackstein Robert (Reprint)
AUTHOR ADDRESS: Harvard Univ, Inst Med, 77 Ave Louis Pasteur,Rm 671, Boston, MA 02115 USA**USA
AUTHOR E-MAIL ADDRESS: rsackstein@rics.bwh.harvard.edu
JOURNAL: Journal of Biological Chemistry 281 (20): p13899-13905 MAY 19 2006 2006
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

19001424 BIOSIS NO.: 200600346819
Comparative analysis of sialomucin and glycolipid E-selectin ligand activities: Effects of HCELL knockdown
AUTHOR: Burdick Monica M (Reprint); Chu Julia T; Knoblauch Christine A; Sackstein Robert
AUTHOR ADDRESS: Brigham and Womens Hosp, Dept Dermatol, Boston, MA 02115 USA**USA
JOURNAL: Glycobiology 15 (11): p1249 NOV 2005 2005
CONFERENCE/MEETING: Meeting of the Society-for-Glycobiology Boston, MA, USA November 09 -12, 2005; 20051109
SPONSOR: Soc Glycobiol
ISSN: 0959-6658
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

4/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18842637 BIOSIS NO.: 200600188032
Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells
AUTHOR: Hanley William D; Napier Susan L; Burdick Monica M; Schnaar Ronald L; Sackstein Robert; Konstantopoulos Konstantinos (Reprint)
AUTHOR ADDRESS: Johns Hopkins Univ, Dept Chem and Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA**USA
AUTHOR E-MAIL ADDRESS: kkonsta1@jhu.edu
JOURNAL: FASEB Journal 19 (14): DEC 2005 2005
ISSN: 0892-6638
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18669741 BIOSIS NO.: 200600015136
CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity
AUTHOR: Hanley William D; Burdick Monica M; Konstantopoulos Konstantinos; Sackstein Robert (Reprint)
AUTHOR ADDRESS: Harvard Inst Med, 77 Ave Louis Pasteur,Room 671, Boston, MA 02115 USA**USA
AUTHOR E-MAIL ADDRESS: kkonsta1@jhu.edu
JOURNAL: Cancer Research 65 (13): p5812-5817 JUL 1 2005 2005
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18417061 BIOSIS NO.: 200510111561
From graft failure to graft-versus-host disease: the central role of glycans in allogeneic bone marrow transplantation
AUTHOR: Sackstein Robert (Reprint)
AUTHOR ADDRESS: Harvard Univ, Inst Med, Boston, MA 02115 USA**USA
JOURNAL: Glycobiology 14 (11): p1067-1068 NOV 04 2004
CONFERENCE/MEETING: Joint Meeting of the Society-for-Glycobiology/Japanese-Society-for-Carbohydrate-Research Honolulu, HI, USA November 17 -20, 2004; 20041117
SPONSOR: Soc Gylcobiol
Japanese Soc Carbohydrate Res
ISSN: 0959-6658
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

4/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18075717 BIOSIS NO.: 200400443636
The bone marrow is akin to skin: HCELL and the biology of hematopoietic stem cell homing
AUTHOR: Sackstein Robert (Reprint)
AUTHOR ADDRESS: Inst Med, Harvard Univ, 77 Ave Louis Pasteur,Room 671, Boston, MA, 02115, USA**USA
AUTHOR E-MAIL ADDRESS: rsackstein@rics.bwh.harvard.edu
JOURNAL: Journal of Investigative Dermatology Symposium Proceedings 9 (3): p215-223 September 2004 2004
MEDIUM: print
ISSN: 1087-0024 (ISSN print)
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

4/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

17801832 BIOSIS NO.: 200400172589
G-CSF mobilization radically upregulates alpha-1,3-fucosyltransferases-4 and -7 generating high avidity E-selectin ligands on circulating nucleated cells.
AUTHOR: Schreiber Taylor H (Reprint); Cain Derek W (Reprint); Dimitroff Charles J (Reprint); Sackstein Robert (Reprint)
AUTHOR ADDRESS: Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA**USA
JOURNAL: Blood 102 (11): p115a November 16, 2003 2003
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

4/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

17794738 BIOSIS NO.: 200400162079
CD44/HCELL is an E- and L-selectin ligand on murine hematopoietic progenitor cells.
AUTHOR: Cain Derek W (Reprint); Schreiber Taylor H (Reprint); Dimitroff Charles J (Reprint); Chung Christine (Reprint); Otero Jaclyn (Reprint); Sackstein Robert (Reprint)
AUTHOR ADDRESS: Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA**USA
JOURNAL: Blood 102 (11): p180b November 16, 2003 2003
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

4/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

17703065 BIOSIS NO.: 200400069321
CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD.
AUTHOR: Milinkovic Mirjana; Antin Joseph H; Hergrueter Charles A; Underhill Charles B; Sackstein Robert (Reprint)
AUTHOR ADDRESS: Harvard Institutes of Medicine, 77 Ave Louis Pasteur, Rm 671, Boston, MA, 02115, USA**USA
AUTHOR E-MAIL ADDRESS: rsackstein@rics.bwh.harvard.edu
JOURNAL: Blood 103 (2): p740-742 January 15, 2004 2004
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/14 (Item 14 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16627075 BIOSIS NO.: 200200220586
Homing and hematopoiesis: HCELL is the principal E-selectin and L-selectin ligand of human hematopoietic stem cells
AUTHOR: Sackstein Robert (Reprint); Dimitroff Charles J (Reprint); Lee Jack Y (Reprint); Fuhlbrigge Robert C (Reprint); Parmar Kalindi; Mauch Peter M; Sandmaier Brenda M
AUTHOR ADDRESS: Dermatology and Medicine, Brigham and Women's Hospital, Boston, MA, USA**USA
JOURNAL: Blood 98 (11 Part 1): p710a November 16, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

4/3/15 (Item 15 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16567681 BIOSIS NO.: 200200161192
Differential L-selectin binding activities of human hematopoietic cell L-selectin ligands, HCELL and PSGL-1
AUTHOR: Dimitroff Charles J; Lee Jack Y; Schor Kenneth S; Sandmaier Brenda M; Sackstein Robert (Reprint)
AUTHOR ADDRESS: Harvard Institutes of Medicine, Harvard Skin Disease Research Center, 77 Ave. Louis Pasteur, Boston, MA, 02115, USA**USA
JOURNAL: Journal of Biological Chemistry 276 (50): p47623-47631 December 14, 2001 2001
MEDIUM: print
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/16 (Item 16 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16299526 BIOSIS NO.: 200100471365
CD44 is the primary L-selectin ligand on human leukemias
AUTHOR: Dimitroff Charles J (Reprint); Schor Kenneth (Reprint); Lee Jack Y (Reprint); Sackstein Robert (Reprint)
AUTHOR ADDRESS: Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA**USA
JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 42 p298 March, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 92nd Annual Meeting of the American Association for Cancer Research New Orleans, LA, USA March 24-28, 2001; 20010324
ISSN: 0197-016X
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

4/3/17 (Item 17 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16153171 BIOSIS NO.: 200100325010
CD44 is a major E-selectin ligand on human hematopoietic progenitor cells
AUTHOR: Dimitroff Charles J; Lee Jack Y; Rafii Shahin; Fuhlbrigge Robert C; Sackstein Robert (Reprint)
AUTHOR ADDRESS: Harvard Institutes of Medicine, 77 Ave. Louis Pasteur, Room 671, Boston, MA, 02115, USA**USA
JOURNAL: Journal of Cell Biology 153 (6): p1277-1286 June 11, 2001 2001
MEDIUM: print
ISSN: 0021-9525
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/18 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

15896636 BIOSIS NO.: 200100068475

A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells
AUTHOR: Dimitroff Charles J; Lee Jack Y; Fuhlbrigge Robert C; Sackstein Robert (Reprint)
AUTHOR ADDRESS: Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Room 671, Boston, MA, 02115, USA**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 97 (25): p13841-13846 December 5, 2000 2000
MEDIUM: print
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/19 (Item 19 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

12704186 BIOSIS NO.: 199598172019
The effects of corticosteroids on lymphocyte recirculation in humans: Analysis of the mechanism of impaired lymphocyte migration to lymph node following methylprednisolone administration
AUTHOR: Sackstein Robert (Reprint); Borenstein Michael
AUTHOR ADDRESS: H Lee Moffitt Cancer Cent., 12902 Magnola Drive., Tampa, FL 33612, USA**USA
JOURNAL: Journal of Investigative Medicine 43 (1): p68-77 1995 1995
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/20 (Item 20 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

12188978 BIOSIS NO.: 199497210263
Effects of methylprednisolone administration on lymphocyte LECAM-1, CD44, and LFA-1 expression: Implications for steroid-induced lymphopenia
BOOK TITLE: Annals of the New York Academy of Sciences; Immunosuppressive and antiinflammatory drugs
AUTHOR: Sackstein Robert
BOOK AUTHOR/EDITOR: Allison A C (Editor); Lafferty K J (Editor); Fliri H (Editor)
AUTHOR ADDRESS: Bone Marrow Transplant Serv., H. Lee Moffitt Cancer Cent., Res. Inst., Univ. South Fla., Coll. Med., Tampa, FL 33612, USA**USA
SERIES TITLE: Annals of the New York Academy of Sciences 696 p417-419 1993
BOOK PUBLISHER: New York Academy of Sciences {a}, 2 East 63rd Street, New York, New York 10021, USA
CONFERENCE/MEETING: Conference Orlando, Florida, USA April 12-15, 1993; 19930412
ISSN: 0077-8923 ISBN: 0-89766-836-7 (paper); 0-89766-835-9 (cloth)
DOCUMENT TYPE: Book; Meeting; Book Chapter; Meeting Paper
RECORD TYPE: Citation
LANGUAGE: English

4/3/21 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

145342289 CA: 145(17)342289z PATENT
HCELL (hematopoietic cell E-selectin/L-selectin ligand) glycoforms of

CD44, a method of increasing the stem cell affinity for selectin, and therapeutic uses
INVENTOR(AUTHOR): Sackstein, Robert
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20060210558 A1 DATE: 20060921
APPLICATION: US 2005272453 (20051110) *US 2000PV240987 (20001018) *US 2001PV297474 (20010611) *US 200142421 (20011018) *US 2004PV627464 (20041112) *US 2005PV673982 (20050422)
PAGES: 70pp., Cont.-in-part of U.S. Ser. No. 42,421. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424140100

IPCR/8 + Level	Value	Position	Status	Version	Action	Source	Office:
A61K-0039/00	A	I	F	B	20060101	20060921	H US
A61K-0039/395	A	I	L	B	20060101	20060921	H US
C12N-0005/08	A	I	L	B	20060101	20060921	H US
C07K-0014/705	A	I	L	B	20060101	20060921	H US

4/3/22 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

145096397 CA: 145(6)96397w PATENT
CD44 glycoforms HCELLs (hematopoietic cell E-selectin/L-selectin ligands), and uses for isolating stem cells and treating and diagnosing disorders
INVENTOR(AUTHOR): Sackstein, Robert
LOCATION: USA
ASSIGNEE: The Brigham and Women's Hospital, Inc.
PATENT: PCT International ; WO 200668720 A2 DATE: 20060629
APPLICATION: WO 2005US40652 (20051110) *US 200142421 (20011018) *US 2004PV627464 (20041112) *US 2005PV673982 (20050422)
PAGES: 137 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

IPCR/8 + Level	Value	Position	Status	Version	Action	Source	Office:
A61K-0048/00	A	I	F	B	20060101	H	US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

4/3/23 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142480790 CA: 142(26)480790v PATENT
Antibodies to HCELL glycoform of CD44
INVENTOR(AUTHOR): Sackstein, Robert
LOCATION: USA
ASSIGNEE: Brigham and Women's Hospital, Inc.
PATENT: PCT International ; WO 200546597 A2 DATE: 20050526
APPLICATION: WO 2004US37138 (20041108) *US 2003PV518353 (20031107)
PAGES: 71 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;

BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/24 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

141289095 CA: 141(18)289095x PATENT
Modulation of hyaluronan and CD44 interaction and uses thereof in treating disorders
INVENTOR(AUTHOR): Sackstein, Robert
LOCATION: USA
ASSIGNEE: Brigham and Women's Hospital, Inc.
PATENT: PCT International ; WO 200482610 A2 DATE: 20040930
APPLICATION: WO 2004US7605 (20040312) *US PV454719 (20030314)
PAGES: 63 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/25 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

139143939 CA: 139(10)143939n PATENT
Preparation of fluorinated glucosamine analogs that inhibit cell migration and inflammation
INVENTOR(AUTHOR): Sackstein, Robert; Dimitroff, Charles J.; Bernacki, Ralph J.; Sharma, Moheswar; Matta, Khushi L.; Paul, Brajeswar
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20030148997 A1 DATE: 20030807
APPLICATION: US 305812 (20021126) *US PV334151 (20011128)
PAGES: 37 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 514062000; A61K-031/7008A; A61K-031/573B; A61K-031/415B; A61K-031/192B

4/3/26 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

137017447 CA: 137(2)17447w PATENT
Hematopoietic cell E-selection/L-selectin ligand polypeptides and methods of use thereof
INVENTOR(AUTHOR): Sackstein, Robert

LOCATION: USA
ASSIGNEE: The Brigham and Women's Hospital, Inc.
PATENT: PCT International ; WO 200244342 A2 DATE: 20020606
APPLICATION: WO 2001US51014 (20011018) *US PV240987 (20001018) *US PV297474 (20010611)
PAGES: 94 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-000/A
DESIGNATED COUNTRIES: CA; JP DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK ; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR
?

20/3/12 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

136324075 CA: 136(21)324075m PATENT
IL-17 receptor-like polypeptides, polynucleotides and antibodies for identification of agonists and antagonists and for diagnosis/treatment of immune diseases
INVENTOR(AUTHOR): Jing, Shuqian
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20020045213 A1 DATE: 20020418
APPLICATION: US 809567 (20010315) *US PV189816 (20000316) *US 724460 (20001128)
PAGES: 54 pp., Cont.-in-part of U.S. Ser. No. 724,460. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435069100; A01K-067/00A; A61K-048/00B; C07H-021/04B; C12P-021/02B; C07K-014/715B

```
 s (agonist?)(10n)(antibod? or immunoglobulin?)(10n)(saccharide? or carbohydrate?
or glycan?)
          562028  AGONIST?
         2252588  ANTIBOD?
          838135  IMMUNOGLOBULIN?
          193199  SACCHARIDE?
          631981  CARBOHYDRATE?
           68296  GLYCAN?
     S19      20  (AGONIST?)(10N)(ANTIBOD? OR
                  IMMUNOGLOBULIN?)(10N)(SACCHARIDE? OR CARBOHYDRATE? OR
                  GLYCAN?)
? rd s19
     S20      14  RD S19  (unique items)
? t s20/3/all

 20/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16048653   BIOSIS NO.: 200100220492
Pro-apoptotic and anti-apoptotic effects of transferrin and
  transferrin-derived glycans on hematopoietic cells and lymphocytes
AUTHOR: Lesnikov Vladimir (Reprint); Lesnikova Marina; Deeg H Joachim
AUTHOR ADDRESS: Clinical Research Division, Fred Hutchinson Cancer Research
  Center, 1100 Fairview Avenue North, D1-100, Seattle, WA, 98109-1024, USA
  **USA
JOURNAL: Experimental Hematology (Charlottesville)  29 (4): p477-489 April,
2001 2001
MEDIUM: print
ISSN: 0301-472X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English


 20/3/2     (Item 2 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

15120192   BIOSIS NO.: 199900379852
Selective secretion and replenishment of discrete mucin glycoforms from
  intestinal goblet cells
AUTHOR: Stanley C Michael; Phillips Thomas E (Reprint)
AUTHOR ADDRESS: Division of Biological Sciences, Univ. of Missouri, Tucker
  Hall, Columbia, MO, 65211-7400, USA**USA
JOURNAL: American Journal of Physiology  277 (1 PART 1): pG191-G200 July,
1999 1999
MEDIUM: print
ISSN: 0002-9513
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English


 20/3/3     (Item 3 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

14386791   BIOSIS NO.: 199800181038
Tyrosine phosphorylation following lectin mediated endothelial cell
  stimulation
AUTHOR: Palmetshofer Alois (Reprint); Robson Simon C; Bach Fritz H
AUTHOR ADDRESS: Inst. Clin. Biochem., Univ. Wuerzburg, Josef-Schneider
  Strasse 2, Bau 4, Room 407, D-97080 Wuerzburg, Germany**Germany
```

JOURNAL: Xenotransplantation 5 (1): p61-66 Feb., 1998 1998
MEDIUM: print
ISSN: 0908-665X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

20/3/4 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

146026053 CA: 146(2)26053c JOURNAL
Induction of long-term lipopolysaccharide tolerance by an agonistic monoclonal antibody to the Toll-like receptor 4/MD-2 complex
AUTHOR(S): Ohta, Shoichiro; Bahrun, Uleng; Shimazu, Rintaro; Matsushita, Hidetomo; Fukudome, Kenji; Kimoto, Masao
LOCATION: Department of Immunology, Saga Medical School, 5-1-1 Nabeshima, Saga, Saga, Japan, 849-8501
JOURNAL: Clin. Vaccine Immunol. (Clinical and Vaccine Immunology) DATE: 2006 VOLUME: 13 NUMBER: 10 PAGES: 1131-1136 CODEN: CVILA6 ISSN: 1556-6811 LANGUAGE: English PUBLISHER: American Society for Microbiology

20/3/5 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

145453676 CA: 145(23)453676t PATENT
Three-dimensional structure of influenza virus hemagglutinin epitope for designing and screening of vaccines, antibodies and agonists/antagonists
INVENTOR(AUTHOR): Aangstroem, Jonas; Miller-Podraza, Halina; Pantzar, Martina; Karlsson, Karl-Anders; Blomqvist, Maria; Heiskanen, Annamari; Niemelae, Ritva; Helin, Jari; Natunen, Jari; Satomaa, Tero; Aitio, Olli
LOCATION: Finland
ASSIGNEE: Glykos Finland Oy
PATENT: PCT International ; WO 2006111616 A1 DATE: 20061026
APPLICATION: WO 2006FI50157 (20060420) *FI 2005405 (20050420) *FI 2006200 (20060227)
PAGES: 184pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

IPCR/8 + Level	Value	Position	Status	Version	Action	Source	Office:
C07K-0007/06	A	I	F	B	20060101	H	FI
C07K-0014/11	A	I	L	B	20060101	H	FI
C07K-0016/10	A	I	L	B	20060101	H	FI
A61K-0038/04	A	I	L	B	20060101	H	FI
A61K-0031/7028	A	I	L	B	20060101	H	FI
C07H-0015/00	A	N	L	B	20060101	H	FI
A61P-0031/16	A	N	L	B	20060101	H	FI

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

20/3/6 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

144348705 CA: 144(19)348705h JOURNAL
Agonistic Antibody to TLR4/MD-2 Protects Mice from Acute Lethal Hepatitis Induced by TNF-α
AUTHOR(S): Akashi-Takamura, Sachiko; Furuta, Takahisa; Takahashi, Koichiro; Tanimura, Natsuko; Kusumoto, Yutaka; Kobayashi, Toshihiko; Saitoh, Shin-ichiroh; Adachi, Yoshiyuki; Doi, Takahiro; Miyake, Kensuke
LOCATION: Division of Infectious Genetics, Institute of Medical Science, University of Tokyo, Tokyo, Japan,
JOURNAL: J. Immunol. (Journal of Immunology) DATE: 2006 VOLUME: 176 NUMBER: 7 PAGES: 4244-4251 CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English PUBLISHER: American Association of Immunologists

20/3/7 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142372158 CA: 142(20)372158m JOURNAL
Generation of a Monoclonal Antibody Agonist to Toll-Like Receptor 4
AUTHOR(S): Cohen, S. B.; Gaskins, C.; Nasoff, M. S.
LOCATION: Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA
JOURNAL: Hybridoma (Hybridoma) DATE: 2005 VOLUME: 24 NUMBER: 1 PAGES: 27-35 CODEN: HYBRAV ISSN: 1554-0014 LANGUAGE: English
PUBLISHER: Mary Ann Liebert, Inc.

20/3/8 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

141394085 CA: 141(24)394085s PATENT
Antibodies specific to STOP-1 protein for agonist/antagonist screening and diagnosis and therapy of proliferative disease and cancer
INVENTOR(AUTHOR): Ackerly, Heidi; Ashkenazi, Avi; Eberhard, David; Frantz, Gretchen; French, Dorothy; Fuh, Germaine; Hongo, Jo-Anne; Lee, Chingwei; Marsters, Scot; Pitti, Robert; Raab, Helga; Soroceanu, Liliana; Varfolomeev, Evgeny; Wolf, Beni
LOCATION: USA
ASSIGNEE: Genentech, Inc.
PATENT: PCT International ; WO 200494476 A2 DATE: 20041104
APPLICATION: WO 2004US11793 (20040416) *US PV463656 (20030416)
PAGES: 265 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07K-016/44A; C07K-014/47B; G01N-033/53B; A61P-035/00B; C12N-015/12B; C12N-015/63B; C12N-015/09B; A61K-031/7088B; C07K-019/00B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

20/3/9 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

141070244 CA: 141(5)70244m PATENT

Agonistic and antagonistic anti-CD40 monoclonal antibodies and fragments for use as immunopotentiating or immunosuppressive agents
INVENTOR(AUTHOR): Mikayama, Toshifumi; Yoshida, Hitoshi; Force, Walker R. ; Chen, Xingjie; Takahashi, Nobuaki
LOCATION: Japan,
PATENT: U.S. Pat. Appl. Publ. ; US 20040120948 A1 DATE: 20040624
APPLICATION: US 693629 (20031023) *US 844684 (20010427) *JP 2001142482 (20010511) *JP 2001310535 (20011005) *US 40244 (20011026) *WO 2002JP4292 (20020426)
PAGES: 77 pp., Cont.-in-part of WO 2002 88,186. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424144100; C12Q-001/68A; A61K-039/395B

20/3/10 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

139099555 CA: 139(7)99555h JOURNAL
Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice
AUTHOR(S): Przetak, Melinda; Chow, Jesse; Cheng, Hongsheng; Rose, Jeffrey ; Hawkins, Lynn D.; Ishizaka, Sally T.
LOCATION: Department of Molecular Biology and Biochemistry, Signal Transduction Research, Andover, MA, 01810, USA
JOURNAL: Vaccine (Vaccine) DATE: 2003 VOLUME: 21 NUMBER: 9-10 PAGES: 961-970 CODEN: VACCDE ISSN: 0264-410X PUBLISHER ITEM IDENTIFIER: 0264-410X(02)00737-5 LANGUAGE: English PUBLISHER: Elsevier Science Ltd.

20/3/11 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

139005343 CA: 139(1)5343n JOURNAL
A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing
AUTHOR(S): Grosse-Hovest, Ludger; Hartlapp, Ingo; Marwan, Wolfgang; Brem, Gottfried; Rammensee, Hans-Georg; Jung, Gundram
LOCATION: Institute for Cell Biology, Department of Immunology, University of Tubingen, Tubingen, Germany,
JOURNAL: Eur. J. Immunol. (European Journal of Immunology) DATE: 2003
VOLUME: 33 NUMBER: 5 PAGES: 1334-1340 CODEN: EJIMAF ISSN: 0014-2980
LANGUAGE: English PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

20/3/12 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

136324075 CA: 136(21)324075m PATENT
IL-17 receptor-like polypeptides, polynucleotides and antibodies for identification of agonists and antagonists and for diagnosis/treatment of immune diseases
INVENTOR(AUTHOR): Jing, Shuqian
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20020045213 A1 DATE: 20020418
APPLICATION: US 809567 (20010315) *US PV189816 (20000316) *US 724460 (20001128)
PAGES: 54 pp., Cont.-in-part of U.S. Ser. No. 724,460. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435069100; A01K-067/00A; A61K-048/00B; C07H-021/04B;

C12P-021/02B; C07K-014/715B

20/3/13 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

135370651 CA: 135(26)370651y PATENT
Receptor from TNF family
INVENTOR(AUTHOR): Boyle, William J.; Hsu, Hailing
LOCATION: USA
ASSIGNEE: Amgen Inc.
PATENT: PCT International ; WO 200185782 A2 DATE: 20011115
APPLICATION: WO 2001US4568 (20010212) *US PV181800 (20000211)
PAGES: 124 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07K-014/52A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW ; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

20/3/14 (Item 11 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

130109134 CA: 130(9)109134a JOURNAL
Soluble saccharides block the inhibition of agonist-induced human platelet aggregation observed after in vitro incubation of human platelet-rich plasma with porcine aortic endothelial cells
AUTHOR(S): Magnusson, Stefan; Romano, Egidio L.; Hallberg, Eva; Wadenvik, Hans; Breimer, Michael E.
LOCATION: Department of Surgery, Sahlgrens University Hospital, S-413 45, Goteborg, Swed.
JOURNAL: Transplant Int. DATE: 1998 VOLUME: 11 NUMBER: 5 PAGES: 345-352 CODEN: TRINE5 ISSN: 0934-0874 LANGUAGE: English PUBLISHER: Springer-Verlag
?